There is the lack of studies investigating the MDM2 and MDM4 associations with the clinical and morphological characteristics such as tumor size, nodal status, histologic grade, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status, proliferation rate, etc. This information might assist as prognostic factor and/or predictive marker for response to treatment of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.